Stock Analysis on Net
Stock Analysis on Net
Stock Analysis on Net without ads!

Allergan Inc. (NYSE:AGN.)

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Analysis of Inventory

Microsoft Excel

Inventory Disclosure

Allergan Inc., balance sheet: inventory

US$ in thousands

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Finished products 188,300 180,000 185,300 167,100 148,200
Work in process 50,500 44,100 41,500 37,500 41,100
Raw materials 57,200 61,200 56,100 45,100 40,100
Inventories 296,000 285,300 282,900 249,700 229,400

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

Finished Products
Finished products exhibited a generally upward trend over the five-year period, increasing from $148.2 million in 2010 to $188.3 million in 2014. Although there was a slight decline between 2012 and 2013, the overall trajectory suggests growth in this inventory category.
Work in Process
Work in process inventory showed a gradual increase from $41.1 million in 2010 to $50.5 million in 2014. The values rose steadily each year except for a minor dip between 2010 and 2011, indicating ongoing investment or accumulation in production phases.
Raw Materials
Raw materials inventory displayed fluctuations, growing from $40.1 million in 2010 to a peak of $61.2 million in 2013 before declining somewhat to $57.2 million in 2014. This suggests some volatility in procurement or usage patterns of raw materials.
Inventories (Total)
Total inventories increased consistently from $229.4 million in 2010 to $296.0 million in 2014. This steady rise highlights an expansion in overall inventory holdings, which may reflect business growth or changes in inventory management strategy.